Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Colorcon
Daiichi Sankyo
Teva
McKinsey
Chinese Patent Office
Federal Trade Commission
Healthtrust

Generated: May 25, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,705,520

« Back to Dashboard

Summary for Patent: 5,705,520
Title: Medicaments
Abstract:The present invention, relates to 3-[2-(dimethylamino)ethyl]-N-methyl-1H-methanesulphonamide sulphate salt (2:1) and pharmaceutically acceptable solvates thereof, and to pharmaceutical compositions containing same. The compound is useful in the treatment of conditions associated with cephalic pain, in particular migraine. The pharmaceutical compositions are particularly useful as intranasal formulations.
Inventor(s): Craig; Joanne (Ware, GB3), Crookes; Derek Leslie (Ware, GB3), Skittrall; Stephen John (Ware, GB3)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:08/651,961
Patent Claims: 1. 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide hemisulphate salt (2:1) or a physiologically acceptable solvate thereof.

2. A pharmaceutical composition which comprises 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide hemisulphate salt (2:1) or a physiologically acceptable solvate thereof as active ingredient together with a pharmaceutically acceptable carrier.

3. A pharmaceutical composition as claimed in claim 2 adapted for intranasal administration.

4. A method of treating a human suffering from or susceptible to cephalic pain which comprises administration of an effective amount of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide hemisulphate salt (2:1) or a physiologically acceptable solvate thereof to the human in need thereof.

5. A method according to claim 4 wherein the 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide hemisulphate salt (2:1) or a physiologically acceptable solvate thereof is administered intranasally.

6. A method according to claim 4 wherein the 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide hemisulphate salt (2:1) or a physiologically acceptable solvate thereof is administered in the form of an aqueous solution.

7. A method according to claim 4 wherein the cephalic pain is caused by migraine.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
McKesson
Accenture
Teva
US Army
Dow
Federal Trade Commission
US Department of Justice
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.